Compare KVUE & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KVUE | TEVA |
|---|---|---|
| Founded | 2022 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9B | 39.2B |
| IPO Year | 2023 | N/A |
| Metric | KVUE | TEVA |
|---|---|---|
| Price | $19.11 | $33.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $19.45 | ★ $38.63 |
| AVG Volume (30 Days) | ★ 19.8M | 5.6M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.82% | N/A |
| EPS Growth | ★ 40.74 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $15,124,000,000.00 | N/A |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | $2.63 | $2.97 |
| P/E Ratio | $75.80 | ★ $28.19 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.02 | $14.99 |
| 52 Week High | $22.87 | $37.35 |
| Indicator | KVUE | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 68.85 | 46.74 |
| Support Level | $16.83 | $30.59 |
| Resistance Level | N/A | $35.33 |
| Average True Range (ATR) | 0.34 | 1.21 |
| MACD | 0.12 | -0.04 |
| Stochastic Oscillator | 96.80 | 48.99 |
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.